// App-Quantinova.ai

524 : Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia First Results Of a Randomized German-French Cooperative Phase III Trial

Researchers

Presenter

  • Carmen D Schweighofer

Principal Investigators

  • Carolin Muller

  • Kirsten Fischer

  • Ursula Vehling-Kaiser

  • Barbara Eichhorst

  • Manuela A. Bergmann

  • Stephan Stilgenbauer

  • Hartmut Dohner

  • Veronique Leblond

  • Michael Hallek

  • Vincent Levy

  • Raymonde Busch

  • Raphael Porcher

  • Petra Langerbeins

  • Bruno Cazin

  • Anna-Maria Fink

  • Brigitte Dreyfus

  • Stefan Ibach

  • Stephane Lepretre

Medical Centers

  • Day Clinic Hematology Oncology Palliative Care, Landshut, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Service -Hematologie, CHU Poitiers, Poitiers, France

  • Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany

  • Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Service -Hematologie Biologique, Hopital Avicenne, Assistance PubliqueHopitaux de Paris AP-HP, Bobigny, France

  • Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Hematology, Hopital Pitie-Salptriere, Paris, France

  • Institute for Medical Statistics and Epidemiology, Technische Universitaet Muenchen, Munich, Germany

  • Unite de Recherche Clinique, Hopital Avicenne, Bobigny, France

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department of Hematology, Centre de Lutte Contre Le Cancer Henri Becquerel, Rouen, France

  • Center of Clinical Epidemiology, Hopital Hotel-Dieu, Paris, France

Locations

  • France

  • Germany

Companies

  • WISP Wissenschaftlic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Circulating tumor cells

  • Immunoglobulin heavy-chain variable region gene

  • Hormone receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved